The Lord knows, we need additional approaches, inside Ituri and Bas-Uele — in DRC, with over 5,500 now afflicted, and over 2,700 dead — and still expanding rather wildly.
Basing its approach on the Zaire model that worked well in prior outbreaks, Egyptian Minipharm (with the assist of its German unit, called ProBioGen) is now ready to test a new vaccine candidate against Bundibugyo, on the ground. Here’s all that, from Fierce BioTech — as ever:
…The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to $16.5 million to push Minapharm’s Bundibugyo vaccine candidate into the clinic, furthering its response to the Ebola outbreak.
In recent months, more than 2,700 people have died in the Bundibugyo ebolavirus outbreak, primarily in the Democratic Republic of Congo. Seeking to suppress what is now the second-largest Ebola outbreak on record, CEPI called (PDF) for proposals from companies with promising vaccine candidates against the pathogen.
Minapharm answered the call. Working with its Berlin-based unit ProBioGen, the Egyptian drugmaker is developing a vaccine candidate based on the modified vaccinia Ankara platform. A similar technology has provided long-term immunity against Zaire ebolavirus, a related pathogen….
Now you know — and the Obama Center is well-worth a cross country trip — if you can secure timed admission tix. I’ll have more here later, including some sample imagery. Smile… a lovely morning here.
नमस्ते
Powerline Lies... 